On October 13, 2022 LianBio, a Princeton-Shanghai company, reported that stopped a Phase III China trial of Truseltiq (infigratinib) following news that Switzerland’s Helsinn Healthcare will stop distributing the liver cancer drug in the US for "business reasons (Press release, LianBio, OCT 13, 2022, View Source [SID1234622020])." The company will request the FDA to withdraw the drug’s approval for cholangiocarcinoma, issued one year ago. Helsinn signed a $2.4 billion partnership deal with BridgeBio of the US to distribute the drug while LianBio acquired greater China rights. LianBio will provide the drug to current China patients and continue a Phase IIa proof-of-concept study of Truseltiq for other indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!